Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Beta-blockers: primary and secondary prevention.

J M Cruickshank1

  • 1Royal Brompton, National Heart and Chest Hospital, Cheshire, England.

Journal of Cardiovascular Pharmacology
|January 1, 1992
PubMed
Summary

Beta-blockers are highly effective for secondary prevention of myocardial infarction and moderately effective for primary prevention in hypertensive men under 65. Early and later interventions with beta-blockers significantly reduce cardiovascular mortality.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Transversely excited atmospheric CO(2) laser radar with heterodyne detection.

Applied optics·2010
Same author

Are we misunderstanding beta-blockers.

International journal of cardiology·2007
Same author

New guidelines on hypertension.

Lancet (London, England)·2006
Same author

The hydration structure of guanidinium and thiocyanate ions: implications for protein stability in aqueous solution.

Proceedings of the National Academy of Sciences of the United States of America·2003
Same author

Renoprotection with antihypertensive agents.

Lancet (London, England)·2002
Same author

Beta-adrenergic blocking drugs in the treatment of hypertension.

Blood pressure·2002

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Coronary heart disease is a leading cause of death in industrialized nations.
  • Syndrome X, characterized by hypertension, obesity, lipid disturbances, and insulin resistance, is common.
  • Beta-blockers show significant efficacy in secondary myocardial infarction prevention, unlike calcium antagonists.

Purpose of the Study:

  • To evaluate the effectiveness of beta-blockers in secondary and primary prevention of myocardial infarction.
  • To compare beta-blocker efficacy with other drug classes like calcium antagonists and diuretics.
  • To assess the impact of timing, formulation, and patient demographics on beta-blocker outcomes.

Main Methods:

  • Review of studies on beta-blocker use in myocardial infarction and hypertension.
  • Analysis of early (intravenous) and late (oral) beta-blocker interventions.

Related Experiment Videos

  • Comparison of beta-blockers with calcium antagonists, diuretics, and ISA-containing beta-blockers.
  • Examination of hydrophilicity/lipophilicity and effects in different age groups and risk profiles.

    • Main Results:

    • Early intravenous beta-blockers reduced cardiovascular mortality by 15% at 1 week.
    • Late oral non-ISA beta-blockers reduced mortality by 30% at 1 year.
    • Beta-blockers are first-line for hypertensive patients <65, especially men, reducing Q-wave MI.
    • In elderly hypertensives, diuretics were more effective for MI prevention than beta-blockers, though beta-blockers are indicated for overt ischemia.

    Conclusions:

    • Beta-blockers are crucial for secondary myocardial infarction prevention.
    • They offer moderate primary prevention benefits in younger hypertensive men.
    • Treatment strategies should be tailored based on patient age, risk factors, and presence of ischemia.